Aktis Oncology, Inc. (AKTS) Stock Grade

About Aktis Oncology, Inc.'s fundamentals

Aktis Oncology is a biotechnology company with a market capitalization of $1.0 billion that demonstrated exceptional revenue growth of 336.9% year-over-year, indicating rapidly expanding commercial activity. However, the company reported a significant net loss in its latest annual statement with a net margin of -980.9%, meaning expenses far exceeded revenues. The company does not pay a dividend, and with no meaningful earnings, a traditional P/E ratio is not applicable. This profile is typical of early-stage biotech firms that are investing heavily in development and commercialization while still operating at a loss.